-

09:25:09 AM

ABEO Stock News

ABEO - Abeona Therapeutics Inc

10/21/21 7:30 AM

Nasdaq : ABEO

conferences

Abeona Therapeutics to Present at Jefferies Gene Therapy/Editing Summit

Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that Vish Seshadri, Ph.D., M.B.A., Chief Executive Officer of Abeona, is scheduled to present at the Jefferies Gene

RHEA-AI

neutral

10/13/21 7:30 AM

Nasdaq : ABEO

clinical trial

Abeona Therapeutics Announces Clinical Data Presentations at Upcoming Scientific Congresses

Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced two presentations of previously disclosed clinical data at upcoming scientific congresses in October 2021. The presentations

RHEA-AI

neutral

10/12/21 7:30 AM

Nasdaq : ABEO

management

Abeona Therapeutics Appoints Gene Therapy Quality Leader Jon Voss as Vice President, Head of Quality

Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced the appointment of Jon Voss as Vice President, Head of Quality. Mr. Voss, who has been advising the Company as a consultant, will

RHEA-AI

neutral

09/21/21 4:01 PM

Nasdaq : ABEO

Abeona Announces New Chairman, Executive Leadership Promotions and Key Talent Additions for Final Push Towards Two Biologics License Application (BLA) Filings

Steven H. Rouhandeh to retire as Chairman of the Board; Michael Amoroso appointed Chairman of the Board Vishwas Seshadri, Ph.D., M.B.A. to become Chief Executive Officer Brendan M. O’Malley, J.D., Ph.D. promoted to General Counsel, Brian Kevany, Ph.D. promoted to Chief Technical Officer, Scott

RHEA-AI

positive

09/07/21 7:30 AM

Nasdaq : ABEO

conferences

Abeona Therapeutics to Present at Upcoming Investor Conferences

Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that members of the company’s management will present and conduct one-on-one meetings at the following virtual investor

RHEA-AI

neutral

08/10/21 7:30 AM

Nasdaq : ABEO

management

Abeona Therapeutics Appoints Edward Carr as Chief Financial Officer

Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced the appointment of Edward Carr as Chief Financial Officer and Principal Financial Officer, effective immediately. Mr. Carr had

RHEA-AI

neutral

07/28/21 4:01 PM

Nasdaq : ABEO

earnings

Abeona Therapeutics Reports Second Quarter Financial Results

Second clinical trial site activated in EB-101 pivotal Phase 3 VIITAL™ study Successful Type B meeting with U.S. FDA; Transpher A study will serve as the pivotal study for ABO-102 in MPS IIIA; Alignment with FDA on primary study endpoint Focusing resources on completing EB-101 and ABO-102 pivotal,

RHEA-AI

positive

07/28/21 7:30 AM

Nasdaq : ABEO

Abeona Therapeutics Announces Successful Type B Meeting with U.S. FDA for ABO-102 AAV-based Gene Therapy in Sanfilippo Syndrome Type A (MPS IIIA)

Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced

RHEA-AI

very positive

07/26/21 7:30 AM

Nasdaq : ABEO

Abeona Therapeutics Announces New MRI Data Showing Increased Brain Volume in Young Patients with Sanfilippo Syndrome Type A (MPS IIIA) After Treatment with ABO-102 Gene Therapy

Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene therapy, today announced magnetic resonance imaging

RHEA-AI

neutral

07/23/21 7:30 AM

Nasdaq : ABEO

clinical trial

Abeona Therapeutics Activates Second Clinical Trial Site in EB-101 Pivotal Phase 3 VIITAL™ Study for Recessive Dystrophic Epidermolysis Bullosa

Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced the activation of a second clinical trial site in its pivotal Phase 3 VIITAL™ study of its investigational EB-101 treatment for

RHEA-AI

neutral

ABEO Data:

IndustryPharmaceutical Preparation Manufacturing
Websiteabeonatherapeutics.com
CeoJoao Siffert
Security nameAbeona Therapeutics Inc
Issue typecs
SectorManufacturing
Sic code2834
Employees76
Tags
- Health Technology
- Pharmaceuticals: Generic
- Manufacturing
- Pharmaceutical Preparation Manufacturing
Address1330 Avenue of the Americas Fl 33
StateNew York
CityNew York
Zip10019-5442
CountryUS
Phone16468134701

ABEO Description:

Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing gene and cell therapies for serious diseases. Abeona's clinical programs include EB-101, its autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa in Phase 3 development, as well as ABO-102 and ABO-101, novel AAV-based gene therapies for Sanfilippo syndrome types A and B (MPS IIIA and MPS IIIB), respectively, in Phase 1/2 development. The Company's portfolio also features AAV-based gene therapies for ophthalmic diseases with high unmet medical needs. Abeona's novel, next-generation AIM™ capsids have shown potential to improve tropism profiles for a variety of devastating diseases. Abeona's fully functional, gene and cell therapy GMP manufacturing facility produces EB-101 for the pivotal Phase 3 VIITAL™ study and is capable of clinical and commercial production of AAV-based gene therapies.